<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="32153">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02688088</url>
  </required_header>
  <id_info>
    <org_study_id>15537</org_study_id>
    <secondary_id>I3Y-MC-JPCB</secondary_id>
    <nct_id>NCT02688088</nct_id>
  </id_info>
  <brief_title>A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body</brief_title>
  <official_title>Effects of Multiple Doses of Abemaciclib on the Pharmacokinetics of Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2D6, and CYP3A Substrates (Caffeine, Warfarin, Dextromethorphan, and Midazolam) in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is known as a &quot;drug interaction study&quot; and is being done to see how abemaciclib
      may affect the blood levels of a drug mixture of commonly used drugs (caffeine, warfarin,
      dextromethorphan, and midazolam) when taken in combination with abemaciclib. Each
      participant will complete screening and four study periods, with the option to continue to
      receive abemaciclib in a safety extension phase. All participants will complete a safety
      follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of Caffeine, S-Warfarin, Dextromethorphan, and Midazolam</measure>
    <time_frame>Baseline through Period 2 Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration versus Time Curve (AUC) of Caffeine, S-Warfarin, Dextromethorphan, and Midazolam</measure>
    <time_frame>Baseline through Period 2 Day 12</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Drug Cocktail</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of drug cocktail (caffeine, warfarin, dextromethorphan, and midazolam) administered orally on Day 1 of Period 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abemaciclib + Drug Cocktail</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abemaciclib administered orally every 12 hours on Days 1 - 12 of Period 2 with a single dose of drug cocktail administered orally on Day 8 of Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abemaciclib - Period 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abemaciclib administered orally every 12 hours on Days 13 to 28 of Period 3. Participants may continue to receive abemaciclib until discontinuation criteria are met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abemaciclib - Period 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abemaciclib administered orally every 12 hours on Days 1 to 28 of Period 4. Participants may continue to receive abemaciclib until discontinuation criteria are met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug Cocktail</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Drug Cocktail</arm_group_label>
    <arm_group_label>Abemaciclib + Drug Cocktail</arm_group_label>
    <other_name>Caffeine + Warfarin + Dextromethorphan + Midazolam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Abemaciclib + Drug Cocktail</arm_group_label>
    <arm_group_label>Abemaciclib - Period 3</arm_group_label>
    <arm_group_label>Abemaciclib - Period 4</arm_group_label>
    <other_name>LY2835219</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have histological or cytological evidence of a diagnosis of cancer that is advanced
             and/or metastatic

          -  Have adequate organ function

          -  Have a performance status of â‰¤2 on the Eastern Cooperative Oncology Group (ECOG)
             scale

          -  Have discontinued all previous therapies for cancer (including chemotherapy,
             radiotherapy, immunotherapy, cancer-related hormonetherapy, and investigational
             therapy) for at least 21 days for myelosuppressive agents or 14 days for
             nonmyelosuppressive agents prior to receiving study drug and have recovered from the
             acute effects of therapy(treatment related toxicity resolved to baseline), except for
             residual alopecia

        Exclusion Criteria:

          -  Require treatment with inducers or inhibitors of cytochrome P450 (CYP)1A2, CYP2C9,
             CYP2D6, and CYP3A within 14 days before the first dose of study drug through the end
             of Period 2

          -  History or presence of significant bleeding disorders

          -  Have known active uncontrolled or symptomatic CNS metastases

          -  Have a primary liver tumor

          -  Have lymphoma or leukemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>IU Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>317-948-0080</phone>
    </contact>
    <investigator>
      <last_name>B H O'Neil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>913-945-7548</phone>
    </contact>
    <investigator>
      <last_name>R P Perez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LCC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>210-593-5250</phone>
    </contact>
    <investigator>
      <last_name>A Patnaik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrialguide.com/EN/studies/cancer/jpcb</url>
    <description>Click here for more information about this study: A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body</description>
  </link>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 14, 2017</lastchanged_date>
  <firstreceived_date>February 17, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dextromethorphan</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
